NCT06504420View on ClinicalTrials.gov

The Safety and Efficiency of Sirolimus in Primary Antiphospholipid Syndrome: a Randomized Control Study

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

October 15, 2024

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2027

Conditions
Primary Antiphospholipid Syndrome
Interventions
DRUG

Sirolimus

Subjects will receive Sirolimus 1.5mg/d for 48 weeks in addition to their ongoing APS treatment regimen

DRUG

Placebo

Subjects will receive Placebo 1.5mg/d for first 24 weeks and Sirolimus 1.5mg/d for next 24 weeks in addition to their ongoing APS treatment regimen

All Listed Sponsors
lead

Peking University People's Hospital

OTHER

NCT06504420 - The Safety and Efficiency of Sirolimus in Primary Antiphospholipid Syndrome: a Randomized Control Study | Biotech Hunter | Biotech Hunter